Funder
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Reference54 articles.
1. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study;Cahn;Lancet,2013
2. Impact of combinations of clinically observed HIV integrase mutations on phenotypic resistance to integrase strand transfer inhibitors (INSTIs): a molecular study;Cheung;J. Antimicrob. Chemother.,2022
3. First demonstration project of long-acting injectable Antiretroviral therapy for persons with and without detectable HIV viremia in an urban HIV clinic;Christopoulos;Clin. Infect. Dis. Ciac 631,2022
4. Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis;Cutrell;AIDS,2021
5. D'Amico, R., Cenoz Gomis, S., Moodley, R., Van Solingen-Ristea, R., Baugh, B., Van Landuyt, E., Van Eygen, V., Min, S., Cutrell, A., Foster, C., Chilton, D., Allard, S.D., Ruiter, A., n.d. Compassionate use of long-acting cabotegravir plus rilpivirine for people living with HIV-1 in need of parenteral antiretroviral therapy. HIV Med. n/a. https://doi.org/10.1111/hiv.13370.
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献